Prosensa (NASDAQ: RNA) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Prosensa to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.
This is a summary of recent recommendations for Prosensa and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Prosensa and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
49.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.9% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Prosensa and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Prosensa Competitors||$207.03 million||-$40.51 million||-67.20|
Prosensa’s peers have higher revenue, but lower earnings than Prosensa. Prosensa is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Prosensa peers beat Prosensa on 5 of the 8 factors compared.
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. The Company’s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company’s platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Receive News & Ratings for Prosensa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prosensa and related companies with MarketBeat.com's FREE daily email newsletter.